Heterozygosity for CMT Type 4 Predicts a Severe Vincristine-induced Polyneuropathy Phenotype: A Case Report and Review of Literature.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
8
6
2018
medline:
15
5
2019
entrez:
8
6
2018
Statut:
ppublish
Résumé
Vincristine (VCR) is a common chemotherapeutic agent used in the treatment of multiple types of pediatric tumors. VCR's adverse effects are well documented and commonly involve peripheral neuropathy via axonal degeneration. Neuropathic severity is dose-dependent, with sensory deficits occurring with as little as 4 mg cumulative dose. Severe peripheral neuropathy is generally rare, but its effects become additive when given to patients with undiagnosed hereditary peripheral neuropathy such as Charcot-Marie-Tooth. We report a case of an effect of VCR administration given to a patient who developed grade 4 neuropathy and was found to be a carrier of Charcot-Marie-Tooth disease type 4.
Identifiants
pubmed: 29877907
doi: 10.1097/MPH.0000000000001230
doi:
Substances chimiques
Vincristine
5J49Q6B70F
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM